

A2
canceled

71. A method of inhibiting the proliferation of cancer cells comprising exposing a cancer cell expressing CD48 to a soluble NAIL polypeptide, whereby the proliferation of said cancer cell is inhibited.

72. A method comprising administering a soluble NAIL polypeptide to an individual in an amount sufficient to stimulate B cells in the individual, increase secretion of IgM by B cells in the individual, stimulate dendritic cells in the individual and/or increase production of TNF α and/or IL-12 by dendritic cells in the individual.--

REMARKS

The specification has been amended to recite the claim to priority applications, and claims 1-36 and 44-47 have been cancelled without prejudice to Applicants' right to present these claims in a future response or application. After amendment, claims 37-43 and 48-72 are pending. New claims 48 to 72 are submitted to point out particularly and precisely that which is regarded as the invention. No new matter has been added by these amendments which are supported by the parent application as filed. For example, basis for the new claims can be found in the specification originally filed as follows.

<u>New Claim</u>	<u>Support As Originally Filed</u>
48	Claim 1
49	Claims 1 and 44-47, and pp. 22-23
50	Claims 2
51	Claims 3 and 44-47
52-57	Claims 4-8
58	Claim 9
59	Claims 10-12
60	Claim 13-15
61	Claim 16
62	pp. 25-26
63-67	Claims 17-21
68-69	Claims 23-26
70	Claims 27-28

71


Claim 29

72

Claims 33-36.

Applicants respectfully request an early and favorable action. If any issues remain outstanding, the Examiner is invited to telephone the undersigned at (206) 470-4847.

Respectfully submitted,



Kathleen Fowler
Registration No. 40,611

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430
KF:em

L:\02-Fowler\1010-US prelim amend.doc